Title
Optimisation of adaptive therapy for advanced Hodgkin lymphoma
UMMS Affiliation
Department of Radiation Oncology; Imaging and Radiation Oncology Core
Publication Date
2019-02-01
Document Type
Response or Comment
Disciplines
Hemic and Lymphatic Diseases | Neoplasms | Oncology | Radiation Medicine
Abstract
Comment on: PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.PMID: 30658935 Clinical Trial.
DOI of Published Version
10.1016/S1470-2045(19)30005-1
Source
Fitzgerald TJ. Optimisation of adaptive therapy for advanced Hodgkin lymphoma. Lancet Oncol. 2019 Feb;20(2):167-168. doi: 10.1016/S1470-2045(19)30005-1. Epub 2019 Jan 15. PMID: 30658934. Link to article on publisher's site
Journal/Book/Conference Title
The Lancet. Oncology
Related Resources
PubMed ID
30658934
Repository Citation
FitzGerald TJ. (2019). Optimisation of adaptive therapy for advanced Hodgkin lymphoma. Radiation Oncology Publications. https://doi.org/10.1016/S1470-2045(19)30005-1. Retrieved from https://escholarship.umassmed.edu/radiationoncology_pubs/107